SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?


To: Michael Rich who wrote (559)2/21/1999 4:28:00 PM
From: Judy  Read Replies (1) | Respond to of 942
 
Mikey, mathematics and eyeballs told me right away that was not possible for WLA's 200-day sma.

Proper entry points ... first entry level 63-65, second entry level 54-55 if it gets there.



To: Michael Rich who wrote (559)2/22/1999 3:07:00 PM
From: Anthony Wong  Respond to of 942
 
Weekly Prescription Trends (22 February 1999):-

Diabetes: WLA's Rezulin new prescription market share decreased 10 basis points to 8.6% this week. Novo Nordisk/Schering-Plough's Prandin remained flat at 2.0% this week.

Cholesterol Lowering: WLA's Lipitor gained 40 basis points to 43.6% market share of new prescriptions. MRK's Zocor remained flat at 25.8% this week. Bristol's Pravachol lost 30 basis points to 16.5%.

askmerrill.com